B. Tombal MD, PhD

Appropriateness of treatment options in patients with metastatic castrationresistant prostate cancer with a focus on radium-223: outcomes of a Belgian multidisciplinary Consensus Meeting

SUMMARY

The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has changed dramatically with the approval of a variety of therapeutic agents including abiraterone acetate, cabazitaxel, docetaxel, enzalutamide and radium-223 dichloride and the introduction of docetaxel and abiraterone acetate in combination with androgen deprivation therapy in newly diagnosed metastatic prostate cancer. Evidence on the optimal sequence of these therapies is scarce. In practice, the most appropriate treatment (sequence) depends on patient and disease characteristics. This article summarises the recommendations of a multidisciplinary group of Belgian experts in sequencing treatments for patients with mCRPC, with a focus on radium-223 dichloride.

(BELG J MED ONCOL 2019;13(6): 240–250)

Read more

The first Belgian multidisciplinary meeting on urological cancers

The Belgian multidisciplinary meeting on urological cancers was initiated as the first national multidisciplinary scientific meeting of medical oncologists (BSMO), urologists (BAU) and radiotherapists (ABRO-BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of uro-oncology.

The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (BSMO); L. Hoekx, S. Joniau, T. Roumeguere (BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (ABRO-BVRO). The first meeting, held in Brussels on March 29th, 2014 was a great success with more than 150 attendees of the different specialisations involved.

(BELG J MED ONCOL 2014;8(5):224–7)

Read more